Can ongoing education by a clinical pharmacist decrease the mean viral burden for patients on protease inhibitor therapy?
Uchishiba, M.A.; Colley, C.; Strausbaugh, L.; Ward, T.
Pharmacotherapy 17(5): 1122
1997
ISSN/ISBN: 0277-0008 Document Number: 265529
Document emailed within 1 workday
Related Documents
Gaillard, M.C.; Reichberg, S.B.; Nogueira, C.M.; Kilroe-Smith, T.A. 1993: Differences in elastase-binding activity of alpha 1-protease inhibitor and alpha 2-macroglobulin for asthma patients and control subjects with various alpha 1-protease inhibitor phenotypes Clinical Chemistry 39(4): 675-679Ritt, M.J.; Hillebrand-Haverkort, M.E.; ten Veen, J.H. 2001: Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy Acta Chirurgiae Plasticae 43(2): 54-56
Marcelin, A.-G.; Flandre, P.; de Mendoza, C.; Roquebert, B.; Peytavin, G.; Valer, L.; Wirden, M.; Abbas, S.; Katlama, C.; Soriano, V.; Calvez, V. 2007: Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients Antiviral Therapy 12(2): 247-252
González, N.; Rodríguez, N.; Tripari, J.; Cantisani, M.; Morán, N.; Soto, S.; Feliciano, C.; Ramos, P.; Yamamura, Y. 1998: RT-PCR comparative study of viral load levels in the HIV positive population in Puerto Rico before and after protease inhibitor regimen implanted Boletin de la Asociacion Medica de Puerto Rico 90(1-3): 16-20
Sherman, K.E.; Shire, N.J.; Cernohous, P.; Rouster, S.D.; Omachi, J.H.; Brun, S.; Da Silva, B. 2005: Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients : Lopinavir-ritonavir versus nelfinavir Clinical Infectious Diseases 41(8): 1186-1195
Besson, C.; Jubault, V.; Viard, J.P.; Pialoux, G. 1998: Ketoacidosis associated with protease inhibitor therapy Aids 12(11): 1399-1400
Cabot de Vega, E.; Fontecha Gómez, B.J.; Solé Arnau, R.; Pedrol Clotet, E. 1999: Peripheral lipodystrophy associated with protease inhibitor therapy Revista Clinica Espanola 199(8): 546-547
Sangraula, H.; Sharma, K.K.; Dwivedi, S. 2001: Antiretroviral protease inhibitor therapy leads to hyperglycaemia, hyperlipidaemia and lipodystrophy National Medical Journal of India 14(6): 347-348
2000: Ritonavir/Saqinavir: dual protease inhibitor combination. Salvage therapy MMW Fortschritte der Medizin 142(3 Suppl): 41
2000: Holding option open for subsequent treatment. Beginning therapy with a protease inhibitor MMW Fortschritte der Medizin 142(3 Suppl): 8-9
Hammer, S.M.; Vaida, F.; Bennett, K.K.; Holohan, M.K.; Sheiner, L.; Eron, J.J.; Wheat, L.Joseph.; Mitsuyasu, R.T.; Gulick, R.M.; Valentine, F.T.; Aberg, J.A.; Rogers, M.D.; Karol, C.N.; Saah, A.J.; Lewis, R.H.; Bessen, L.J.; Brosgart, C.; DeGruttola, V.; Mellors, J.W. 2002: Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial JAMA 288(2): 169-180
Bard, J-Marie.; Lassalle, Régis.; Capeau, J.; Bach-Ngohou, K.; Nazih-Sanderson, Fçoise.; Rémy, Gérard.; Reynes, J.; Ecobichon, J-Luc.; Savès, M.; Raffi, Fçois. 2006: Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy Antiviral Therapy 11(3): 361-370
Piroth, L.; Grappin, M.; Waldner, A.; Sgro, C.; Duong, M.; Buisson, M.; Chavanet, P.; Portier, H. 1999: Discontinuing protease inhibitor treatment of HIV-1 patients for intolerance. Longitudinal study of 309 patients Presse Medicale 28(8): 381-387
Galegov, G.A. 2007: Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS Antibiotiki i Khimioterapiia 52(1-2): 42-45
Anderson, B.L.; Firnhaber, C.; Liu, T.; Swarts, A.; Siminya, M.; Ingersoll, J.; Caliendo, A.M.; Cu-Uvin, S. 2012: Effect of trichomoniasis therapy on genital HIV viral burden among African women Sexually Transmitted Diseases 39(8): 638-642
Ozeki, I.; Karino, Y.; Toyota, J. 2011: Efficacy of the NS3-4A protease inhibitor telaprevir in patients with chronic hepatitis C Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 4): 267-274
Knobel, H.; Goday, A.; Grau, S. 1998: Protease inhibitor-associated hypertriglyceridemia and diabetes mellitus in HIV-infected patients Medicina Clinica 111(15): 599
Traber, D.L.; Adams, T.; Sziebert, L.; Williams, P.; Traber, L.D. 1984: Failure of a protease inhibitor to affect the cardiopulmonary response to endotoxin when combined with a cyclooxygenase inhibitor Circulatory Shock 13(4): 319-323
Bacq, Y.; Schillio, Y.; Brechot, J.F.; De Muret, A.; Dubois, F.; Metman, E.H. 1993: Decrease of haptoglobin serum level in patients with chronic viral hepatitis C Gastroenterologie Clinique et Biologique 17(5): 364-369
Taylor, B.S.; Hunt, G.; Abrams, E.J.; Coovadia, A.; Meyers, T.; Sherman, G.; Strehlau, R.; Morris, L.; Kuhn, L. 2011: Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa AIDS research and human retroviruses 27(9): 945-956